Trial · NCT06726395
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
NCT06726395, Phase 4, Recruiting, Region Skane
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia. Trials, record NCT06726395. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06726395
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
- NCT number
- NCT06726395
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 420 participants, estimated
- Lead sponsor
- Region Skane
- Conditions
- Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia), Staphylococcus (S.) Aureus Infection
- Interventions
- Penicillin G_1200mg, cloxacillin
- First posted
- 2024-12-10
- Last updated
- 2026-04-30
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival at 90 days without any treatment complications | From enrollment to 90 days after end of treatment | Complications are defined as having any of; relapse within 90 days after treatment finish, need of change or addition of antibiotics due to side effects or treatment failure or adverse events. |
| Secondary | Mortality at 90 days | From enrollment to 90 days after end of treatment | All cause mortality within 90 days from enrollment |
| Secondary | Relapse 90 days after end of treatment | From enrollment to 90 days after end of treatment | Relapse with positive culturing from sterile sites or high suscpition of clinical relapse |
| Secondary | Cumulative frequency of side effects within 90 days | From enrollment until 90 days. | all side effects registered as a cumulative frequence |
| Secondary | Cumulative frequence of change or addition of antibiotic treatment due to sideeffects or treatment failure | from enrollment to end of treatment duration up to 90 days | Every time additional antibiotics or change in antibiotic treatment is made due to either side effects or treatment failure (according to treating doctor) |
| Secondary | Decrease of Bacterial DNA in blood samples | From enrollment and first 5 days | Bacterial DNA tested the first 5 days during study treatment. |
| Other | Days with intravenous antibiotics | From enrollment and until end of treatment | Differences between treatment groups |
| Other | Different outcome measures stratified by diagnosis | From enrollment and up to 90 days after end of treatment | 90 days mortality, relapse 90 days after end of treatment, cumulative side effects stratified by diagnosis |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06726395
GET https://conductscience.org/api/trials/v1/NCT06726395/registered